Endocrinology, Vol 135, 2001-2005, Copyright © 1994 by Endocrine Society

ARTICLES

Raloxifene preserves bone strength and bone mass in ovariectomized rats

CH Turner, M Sato and HU Bryant
Department of Ortopaedic Surgery, Indiana University Medical Center, Indianapolis 46202.

We investigated the effects of raloxifene, a nonsteroidal benzothiophene, on bone strength in ovariectomized rats and compared them with estrogen treatment. Sixty ovariectomized Sprague-Dawley rats were divided into three groups for treatment with orally dosed raloxifene (3 mg/kg), ethynyl estradiol (EE, 0.1 mg/kg), or vehicle. A fourth group of 20 rats that underwent sham ovariectomies and received vehicle was used for comparison. Treatments began 3 days after ovariectomy and continued for 6 months. Raloxifene treatment resulted in greater bone strength in the lumbar vertebrae (P < 0.05) and femoral neck (P < 0.01) and greater bone mineral density at the proximal tibia (P < 0.001) and lumbar vertebrae (P < 0.001) when compared with vehicle- treated ovariectomized animals. The positive effects on bone biomechanical properties from raloxifene treatment were not different than those associated with EE treatment. Raloxifene did not cause a significant increase in uterine weight, whereas EE treatment resulted in uterine weight increased 4-fold over vehicle-treated ovariectomized controls. Therefore, in rats, raloxifene has beneficial effects on bone biomechanics that are equivalent to those of EE treatment without substantial effects on the uterus.

This article has been cited by other articles:

				E. A. Booth, M. Marchesi, E. J. Kilbourne, and B. R. Lucchesi 17{beta}-Estradiol as a Receptor-Mediated Cardioprotective Agent J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 395 - 401. [Abstract] [Full Text] [PDF]

				D. P. McDonnell, C. E. Connor, A. Wijayaratne, C.-y. Chang, and J. D. Norris Definition of the Molecular and Cellular Mechanisms Underlying the Tissue-selective Agonist/Antagonist Activities of Selective Estrogen Receptor Modulators Recent Prog. Horm. Res., January 1, 2002; 57(1): 295 - 316. [Abstract] [Full Text] [PDF]

				A. Saitta, D. Altavilla, D. Cucinotta, N. Morabito, N. Frisina, F. Corrado, R. D'Anna, A. Lasco, G. Squadrito, A. Gaudio, et al. Randomized, Double-Blind, Placebo-Controlled Study on Effects of Raloxifene and Hormone Replacement Therapy on Plasma NO Concentrations, Endothelin-1 Levels, and Endothelium-Dependent Vasodilation in Postmenopausal Women Arterioscler. Thromb. Vasc. Biol., September 1, 2001; 21(9): 1512 - 1519. [Abstract] [Full Text] [PDF]

				J. E. Compston Sex Steroids and Bone Physiol Rev, January 1, 2001; 81(1): 419 - 447. [Abstract] [Full Text] [PDF]

				H. Z. Ke, H. Qi, D. T. Crawford, K. L. Chidsey-Frink, H. A. Simmons, and D. D. Thompson Lasofoxifene (CP-336,156), a Selective Estrogen Receptor Modulator, Prevents Bone Loss Induced by Aging and Orchidectomy in the Adult Rat Endocrinology, April 1, 2000; 141(4): 1338 - 1344. [Abstract] [Full Text] [PDF]

				Q. Qu, H. Zheng, J. Dahllund, A. Laine, N. Cockcroft, Z. Peng, M. Koskinen, K. Hemminki, L. Kangas, K. Vaananen, et al. Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats Endocrinology, February 1, 2000; 141(2): 809 - 820. [Abstract] [Full Text] [PDF]

				G. A. Figtree, Y.-q. Lu, C. M. Webb, and P. Collins Raloxifene Acutely Relaxes Rabbit Coronary Arteries In Vitro by an Estrogen Receptor–Dependent and Nitric Oxide–Dependent Mechanism Circulation, September 7, 1999; 100(10): 1095 - 1101. [Abstract] [Full Text] [PDF]

				N. F. Col, S. G. Pauker, R. J. Goldberg, M. H. Eckman, R. K. Orr, E. M. Ross, and J. B. Wong Individualizing Therapy to Prevent Long-term Consequences of Estrogen Deficiency in Postmenopausal Women Arch Intern Med, July 12, 1999; 159(13): 1458 - 1466. [Abstract] [Full Text] [PDF]

				V. C. Jordan and M. Morrow Tamoxifen, Raloxifene, and the Prevention of Breast Cancer Endocr. Rev., June 1, 1999; 20(3): 253 - 278. [Abstract] [Full Text]

				J. F. Couse and K. S. Korach Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us? Endocr. Rev., June 1, 1999; 20(3): 358 - 417. [Abstract] [Full Text]

				Y. Ishimi, C. Miyaura, M. Ohmura, Y. Onoe, T. Sato, Y. Uchiyama, M. Ito, X. Wang, T. Suda, and S. Ikegami Selective Effects of Genistein, a Soybean Isoflavone, on B-Lymphopoiesis and Bone Loss Caused by Estrogen Deficiency Endocrinology, April 1, 1999; 140(4): 1893 - 1900. [Abstract] [Full Text]

				W. Khovidhunkit and D. M. Shoback Clinical Effects of Raloxifene Hydrochloride in Women Ann Intern Med, March 2, 1999; 130(5): 431 - 439. [Abstract] [Full Text] [PDF]

				M. Sato, C. H. Turner, T. Wang, M. D. Adrian, E. Rowley, and H. U. Bryant LY353381.HCl: A Novel Raloxifene Analog with Improved SERM Potency and Efficacy In Vivo J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 1 - 7. [Abstract] [Full Text]

				R. C. Cole, J. A. Flaws, T. L. Bush, M. N. Friedman, P. D. Delmas, B. H. Mitlak, and C. Christiansen Effects of Raloxifene in Postmenopausal Women N. Engl. J. Med., April 30, 1998; 338(18): 1313 - 1314. [Full Text]

				H. Z. Ke, V. M. Paralkar, W. A. Grasser, D. T. Crawford, H. Qi, H. A. Simmons, C. M. Pirie, K. L. Chidsey-Frink, T. A. Owen, S. L. Smock, et al. Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models Endocrinology, April 1, 1998; 139(4): 2068 - 2076. [Abstract] [Full Text] [PDF]

				T. Österman, L. Laurén, P. Kuurtamo, R. Hannuniemi, P. Isaksson, K. Kippo, Z. Peng, H. K. Väänänen, and R. Sellman The Effect of Orally Administered Clodronate on Bone Mineral Density and Bone Geometry in Ovariectomized Rats J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 312 - 316. [Abstract] [Full Text]

				P. D. Delmas, N. H. Bjarnason, B. H. Mitlak, A.-C. Ravoux, A. S. Shah, W. J. Huster, M. Draper, and C. Christiansen Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women N. Engl. J. Med., December 4, 1997; 337(23): 1641 - 1647. [Abstract] [Full Text] [PDF]

				T. Österman, T. Virtamo, L. Laurén, K. Kippo, I. Pasanen, R. Hannuniemi, K. Väänänen, and R. Sellman Slow-Release Clodronate in Prevention of Inflammation and Bone Loss Associated with Adjuvant Arthritis J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 1001 - 1007. [Abstract] [Full Text]

				R. F. Kauffman, W. R. Bensch, R. E. Roudebush, H. W. Cole, J. S. Bean, D. L. Phillips, A. Monroe, G. J. Cullinan, A. L. Glasebrook, and H. U. Bryant Hypocholesterolemic Activity of Raloxifene (LY139481): Pharmacological Characterization as a Selective Estrogen Receptor Modulator J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 146 - 153. [Abstract] [Full Text]